InvestorsHub Logo
Followers 840
Posts 120462
Boards Moderated 18
Alias Born 09/05/2002

Re: None

Thursday, 02/23/2017 6:52:11 PM

Thursday, February 23, 2017 6:52:11 PM

Post# of 875
MRK effectively discontinues MK-3682, the HCV nucleoside obtained in the acquisition of Idenix:

https://www.sec.gov/Archives/edgar/data/310158/000162828017001659/a8-k2017_2x23item206xmater.htm

See #msg-126517784 (bottom) and #msg-103051902 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRK News